CHIMERAL AND HUMANIZED ANTIBODIES TO CD44 THAT ARE MEDIATED BY CYTOTOXICITY AGAINST CANCER CELLS

摘要

1. A method of reducing a breast tumor in a human or prostate gland in a mammal, wherein at least one antigen epitope is expressed in a breast tumor in a human or prostate gland that specifically binds to an isolated monoclonal antibody produced by a hybridoma cell line that is deposited in ATCC under registration number PTA-4621, or its corresponding CDMAB, where CDMAB is characterized by its ability to competitively inhibit the binding of isolated monoclonal antibodies and with its target antigen, which consists in administering to the mammal a monoclonal antibody or its corresponding CDMAB in an amount effective to reduce the tumor load in the mammal with breast or prostate cancer. ! 2. The method according to claim 1, in which the selected monoclonal antibody is conjugated to a cytotoxic fragment. ! 3. The method according to claim 2, in which the cytotoxic fragment is a radioactive isotope. ! 4. The method according to claim 1, in which the selected monoclonal antibody or its corresponding CDMAB activates complement. ! 5. The method according to claim 1. wherein the isolated monoclonal antibody or its corresponding CDMAB mediates antibody-dependent cell-dependent cytotoxicity. ! 6. The method according to claim 1, wherein the isolated monoclonal antibody is a humanized antibody of an isolated monoclonal antibody produced by a hybridoma cell line that is deposited in ATCC under accession number PTA-4621, or an antigen-binding fragment derived from a humanized antibody. ! 7. The method according to claim 1, in